Repligen Co. (NASDAQ:RGEN) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc reduced its holdings in Repligen Co. (NASDAQ:RGEN) by 20.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 88,818 shares of the biotechnology company’s stock after selling 22,803 shares during the quarter. Ensign Peak Advisors Inc owned 0.16% of Repligen worth $11,196,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in RGEN. Andra AP fonden acquired a new position in shares of Repligen during the second quarter valued at $25,000. YHB Investment Advisors Inc. acquired a new position in Repligen during the 1st quarter valued at about $26,000. International Assets Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter worth about $33,000. Lazard Asset Management LLC lifted its stake in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the period. Finally, Rothschild Investment LLC bought a new position in shares of Repligen in the second quarter valued at approximately $57,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. UBS Group decreased their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Wells Fargo & Company started coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $188.38.

Repligen Stock Down 1.8 %

RGEN stock opened at $140.43 on Tuesday. The company’s 50 day simple moving average is $147.66 and its 200-day simple moving average is $154.56. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm has a market capitalization of $7.85 billion, a P/E ratio of 561.72, a P/E/G ratio of 4.14 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. Repligen’s revenue was down 3.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.53 earnings per share. As a group, equities research analysts anticipate that Repligen Co. will post 1.45 EPS for the current year.

Insider Buying and Selling at Repligen

In related news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.